Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
about
Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systemsDistribution of doxorubicin in rats undergoing ultrasonic drug deliveryA phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemiaInverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia.Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.An Alpha-1A Adrenergic Receptor Agonist Prevents Acute Doxorubicin Cardiomyopathy in Male Mice.Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacyTumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.Antitumor activity of photodynamic therapy performed with nanospheres containing zinc-phthalocyanine.Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workersMass spectrometry in the pharmacokinetic studies of anticancer natural products.Anticancer activity of salicin and fenofibrate.Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.Non-invasive synergistic treatment of brain tumors by targeted chemotherapeutic delivery and amplified focused ultrasound-hyperthermia using magnetic nanographene oxide.Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs.Epirubicin permeation of personal protective equipment can induce apoptosis in keratinocytes.Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.Time-targeted therapy (TTT): proof of principle using doxorubicin and radiation in a cultured cell system.Immunocytochemistry for drugs containing an aliphatic primary amino group in the molecule, anticancer antibiotic daunomycin as a model.Development of a single vial kit formulation of [99mTc]-labeled doxorubicin for tumor imaging and treatment response assessment-preclinical evaluation and preliminary human results.Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.Transcriptional analysis of doxorubicin-induced cardiotoxicity.Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens.Evaluation of Apoptosis in Multipotent Hematopoietic Cells of Bone Marrow by Anthracycline Antibiotics.Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats.In vivo evaluation of doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes (PolyDoxSome) using DMBA-induced mammary carcinoma rat model and comparison with marketed LipoDox™.Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia.Versatile injectable supramolecular hydrogels containing drug loaded micelles for delivery of various drugs
P2860
Q27025606-C4E1C603-CCBA-4711-943C-89664341D759Q30404975-9DAF4E79-690C-45AE-9E5D-797A6BC93EA5Q34014818-FEAE8FD3-7D99-424C-A056-657600E60FEBQ34829963-3D5414B2-EF05-4C32-A3AC-A4794C7D2D20Q35996715-C78EBDDF-B6C8-484F-832D-263338D1954FQ36099606-8C8CDCD3-3B83-485B-B24A-8BE46E4DBFD2Q36247553-3643ABA5-28C0-465D-8907-D15D18913154Q36497582-B3A49A53-1684-4EC9-960F-8EBF0B5069B3Q37117472-5B98D079-70E5-45BF-AD26-04BADF8FAE4FQ37389006-4963DD51-260E-4223-9F4D-7E1381C22AA6Q37434372-8CB84CB3-9E4B-4115-A4EA-77508089E67CQ37631325-7E5FB45B-DE51-47ED-A015-E3AEA51B1936Q38568180-368D804B-93A1-40FA-8AA7-8E98244013FEQ38696610-1B9D0C6E-D983-4585-91A5-9876B44BA007Q38737388-11652F09-E355-435A-B217-E20B10626223Q39146745-C71B923F-ED07-41B4-B2D6-474A1F5CEC39Q39314472-0BAD4050-FFA6-4510-9743-CEFF339609FDQ39351905-D2456595-59A8-4B70-80F6-AED6E18B7B63Q39570922-9F9B725D-BD04-4C97-9156-CCFD0EA1297DQ40121128-E2AD139F-355D-448A-9400-8DFC617122EBQ40439716-C5BA970A-DE96-49BE-8717-F80C27C44C13Q40945725-9FD914BA-3D8C-4171-A7E5-3B065B6BD343Q41767370-1FA8B89D-5890-40BA-98BF-90522DB0A228Q46769518-3C13D969-2BD8-4AE8-B8C0-D9CEE8578B37Q46784439-A120CE22-7C3E-4295-A7EF-C2210C839C21Q46873284-41AB5908-A9BA-4468-846E-BB5FDA28D52CQ46930825-1C8B5082-5346-4401-82FB-B054CB6F253FQ51334073-C04167F0-4202-4099-BBA9-46B011D22C5BQ51909505-62D1C999-F4E7-4862-9179-4AB4F1BD9057Q57347960-A0768451-5E08-442B-AB80-8084A3A76820
P2860
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@ast
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@en
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@nl
type
label
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@ast
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@en
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@nl
prefLabel
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@ast
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@en
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
@nl
P50
P1476
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs
@en
P2093
Mario Del Tacca
Stefano Fogli
P304
P356
10.2165/00003088-200241060-00004
P577
2002-01-01T00:00:00Z
P6179
1018296676